- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Segment 10 - Paying for Combination Therapies
Michael Kolodziej, MD, considers the benefit of combination therapy vs sequential and whether the increased toxicity of combination therapy is worth it.
Michael Kolodziej, MD, considers the benefit of combination therapy vs sequential and whether the increased toxicity of combination therapy is worth it.
If there are promising results for combination therapies, the payers will have to figure out the best population for the therapy and how it will be paid for, he said.
“I think there is a common misconception that when payers make coverage policy decisions, and I can speak only about oncology because I do not know about anything else, that they look at the price tag first and the evidence second,” he said. “That is really not how it works. So, I think the evidence is looked at first and then you start thinking about ‘how do we manage the cost?’”
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot
March 18th 2025Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.
Read More
For Neuromuscular Disease Community, an Era of Opportunities and Threats
March 17th 2025Robert Califf, MD, former commissioner of the FDA, delivered a keynote address at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference that highlighted the enormous opportunities for progress in neuromuscular disease care amid a changing policy environment.
Read More
